David Burt

APOLLO‐2: A Randomized, Placebo and Active‐Controlled Phase <scp>III</scp> Study Investigating Oliceridine ( <scp>TRV</scp> 130), a G Protein–Biased Ligand at the μ‐Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty

Neil Singla, Franck Skobieranda, David G. Soergel et al. · Pain Practice · 2019 · 160 citations · Full text

A randomized, Phase IIb study investigating oliceridine (TRV130), a novel &amp;micro;-receptor G-protein pathway selective (&amp;micro;-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty

Neil Singla, Harold S. Minkowitz, David G. Soergel et al. · Journal of Pain Research · 2017 · 143 citations · Full text

&lt;p&gt;APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the &amp;micro;-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy&lt;/p&gt;

Eugene R. Viscusi, Franck Skobieranda, David G. Soergel et al. · Journal of Pain Research · 2019 · 143 citations · Full text

Oliceridine (TRV130), a Novel G Protein–Biased Ligand at the μ‐Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. I: Development of a Pharmacokinetic/Pharmacodynamic Model

Michael J. Fossler, Brian M. Sadler, Colm Farrell et al. · The Journal of Clinical Pharmacology · 2018 · 40 citations

Evaluating the Incidence of Opioid-Induced Respiratory Depression Associated with Oliceridine and Morphine as Measured by the Frequency and Average Cumulative Duration of Dosing Interruption in Patients Treated for Acute Postoperative Pain

Sabry Ayad, Mark A. Demitrack, David Burt et al. · Clinical Drug Investigation · 2020 · 39 citations · Full text